ADMA Adma Biologics PE ratio, current and historical analysis

?
Relative Growth: Rel. Growth: 49
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 70
Relative Profitability: Rel. Profitability: 90

As of Jun 3, 2026, the Adma Biologics stock's PE ratio is 11.25. This takes into account the latest EPS of $0.69 and stock price of $7.76. The PE ratio marks a decrease of 44% from its last 4 quarters average of 20.0.

ADMA PE ratio history

How has ADMA's PE ratio performed in the past

The PE ratio of Adma Biologics has averaged 33.25 over the last two years. The current P/E ratio of 11.25 is 66% lower than the historical average. Looking back at the last two years, ADMA's PE ratio peaked in the Jun 2024 quarter at 74.53, when the price was $11.18 and the EPS was $0.15. The lowest point was in the Mar 2026 quarter, when it reached 13.06 with a price of $9.01 and an EPS of $0.69.

Today
11.57
Average
33.25
Median
21.62
Minimum
13.06
Maximum
74.53

Adma Biologics PE ratio by year

Maximum annual increase: 45.79% in 2025

Year PE ratio PE change Price EPS
2025 29.42 45.79% $18.24 $0.62
2024 20.18 N/A $17.15 $0.85
2023 N/A N/A $4.52 -$0.13
2022 N/A N/A $3.88 -$0.33
2021 N/A N/A $1.41 -$0.51
2020 N/A N/A $1.95 -$0.88
2019 N/A N/A $4 -$0.89
2018 N/A N/A $2.39 -$1.45
2017 N/A N/A $3.21 -$1.91
2016 N/A N/A $5.12 -$1.61
2015 N/A N/A $8.07 -$1.73
2014 N/A N/A $11.17 -$1.81
2013 N/A N/A $7.8 -$2.38
2012 N/A N/A N/A -$1.39
2011 N/A N/A N/A -$16.72

Adma Biologics PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Mar 2026 13.06 -55.61% $9.01 $0.69
Dec 2025 29.42 76.59% $18.24 $0.62
Sep 2025 16.66 -19.48% $14.66 $0.88
Jun 2025 20.69 -8.25% $18.21 $0.88
Mar 2025 22.55 11.74% $19.84 $0.88
Dec 2024 20.18 -70.72% $17.15 $0.85
Sep 2024 68.93 -7.51% $19.99 $0.29
Jun 2024 74.53 N/A $11.18 $0.15
Mar 2024 N/A N/A $6.6 -$0.02
Dec 2023 N/A N/A $4.52 -$0.13
Sep 2023 N/A N/A $3.58 -$0.11
Jun 2023 N/A N/A $3.69 -$0.2
Mar 2023 N/A N/A $3.31 -$0.24
Dec 2022 N/A N/A $3.88 -$0.33
Sep 2022 N/A N/A $2.43 -$0.35

ADMA Price vs fair value

How does ADMA's price compare to its estimated fair value based on its growth

ADMA average PE ratio chart

What is the average PE ratio of ADMA for the past years

The current PE ratio of ADMA is lower than its 3, 5 and 10-year averages.

3-year avg
33.25
5-year avg
33.25
10-year avg
33.25
15-year avg
N/A

PE comparison

With a price to earnings (P/E) of 11.25, ADMA ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 23.02, Adma Biologics's price to earnings (P/E) is 51% lower.

ADMA PE vs peers

What is ADMA's PE ratio compared to its peers

ADMA's PE ratio stands lower than its peer stock RGEN.

Stock name PE ratio Market cap
ADMA Adma Biologics Inc 11.57 $1.85B
RGEN Repligen Corp 137.61 $7.14B
NVAX Novavax Inc N/A $1.67B
CVM Cel Sci Corp N/A $12.82M

Frequently asked questions

What is Adma Biologics's PE ratio?

ADMA's price to earnings ratio is 11.25 as of Jun 3, 2026.

What is the 3-year average PE ratio for Adma Biologics (ADMA)?

Over the last 3 years, the average price to earnings ratio for ADMA stock is 33.25.

What is the 5-year average PE ratio for Adma Biologics (ADMA)?

Over the last 5 years, the average price to earnings ratio for ADMA stock is 33.25.

What is the highest PE ratio for ADMA?

Over the last two years, the Jun 2024 quarter recorded the highest quarterly PE ratio at 74.53.

How does the current PE ratio for ADMA compare to its historical average?

ADMA's price to earnings ratio is currently 66% below its 2-year historical average.

How is ADMA's PE ratio calculated (Adma Biologics PE ratio formula)?

The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jun 3, 2026), Adma Biologics's share price is $7.76. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.69. Therefore, Adma Biologics's PE ratio for today is 11.25. PE RATIO(11.25) = STOCK PRICE($7.76) / TTM EPS($0.69)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.